
Published On: Nov 2020
Published On: Nov 2020
Acid Neutralizers Segment Held Largest Share of Gastrointestinal Drugs Market in 2019
According to our new market research study on “South and Central America Gastrointestinal Drugs Market to 2027 – Regional Analysis and Forecast – by Drug Class, Route of Administration, Application, and Distribution Channel” the market is expected to reach US$ 5,632.72 million by 2027 from US$ 4,160.28 million in 2019; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027. The report provides trends prevailing in the South and Central America gastrointestinal drugs market and the factors driving the market growth along with those hindering it.
In 2019, the acid neutralizers segment accounted for the highest share of the market. However, the biologics segment is expected to be the fastest-growing during the forecast period. The CAGR of the biologics segment has the highest CAGR in the forecast period. The growth of the segment is attributed to growing product development and increasing product launches in the market.
The growth of the South and Central America Gastrointestinal Drugs market is mainly attributed to rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics. However, side effects associated with the drugs will restrict the market growth.
Celltrion Healthcare Co.,Ltd; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; AstraZeneca; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the South and Central America Gastrointestinal Drugs market.
The Report Segments South and Central America Gastrointestinal Drugs Market as Follows:
South and Central America Gastrointestinal Drugs Market – By Drug Class
South and Central America Gastrointestinal Drugs Market – By Route of Administration
South and Central America Gastrointestinal Drugs Market – By Application
South and Central America Gastrointestinal Drugs Market – By Country